Wake Forest ALS Center

10/16/2020

Check out this video to learn more about the ALS Platform Study.

Learn more about this groundbreaking trial, designed to accelerate the development of effective treatments for people in ALS.

10/16/2020

WE ARE READY TO ROLL IN THIS BREAKTHROUGH CLINICAL TRIAL!!! This study simultaneously evaluates several ALS drugs to slow progression and in theory never ends until we find a CURE! There is a 25% risk of placebo. PALS must have had ALS < 3 years and have breathing > 50% of normal.

What patients need to know about participating in the HEALEY ALS Platform Trial.

10/16/2020

This is the 2nd part of the NEJM article mentioned in earlier post. In this study, PALS lived 6.5 months longer if they were taking the active drug. It is well-tolerated but like all good medicines...tastes awful! The FDA will determine if this study is adequate for approval or if a larger study is needed. Wake Forest thanks all the PALS that were involved with this study here.

Introduction An orally administered, fixed‐dose coformulation of sodium phenylbutyrate‐taurursodiol (PB‐TURSO) significantly slowed functional decline in a randomized, placebo‐controlled, phase 2 tr...

10/01/2020

Excited to be in Virtual Clearwater Beach (which looks a lot like my office) for the NEALS meeting learning about new research tools and drugs in ALS! NEALS is the foremost clinical trial group in ALS and WF has been contributing to the consortium for about 20 years. The survival data from the AMX-0035 study performed at Wake Forest and elsewhere looks very good. I expect it will be published within a few weeks and I can post more then. There are also lots of virtual clinical trials tools in development that would reduce the need to come in to the medical center for study visits. These link up through your smart phone for scales, activity (ie steps/day) and even breathing measurements.

09/11/2020

We are thrilled to be first and very grateful to patient #1 to get this study rolling. Non-bulbar onset and breathing better 70% and you could be be #2!

Randomized, open-label, multi-center, dose optimization study expected to evaluate 80 patients with mild- to moderate-stage ALS

09/04/2020

We are thrilled that the Centaur study showed positive finding and hope for even better news when the survival data comes out soon. I hope this means the long gaps between new medicines for ALS is over and also hope these drugs will work together to prolong life and function for our PALS. We honor the 8 PALS from WF ALS Center that participated in this study.

08/25/2020

We are very excited about this trial which has a lot of benefits for our PALS. It is a bit complex so think about tuning in to this if you are interested.

Virtual Webinar & Discussion: HEALEY ALS Platform Trial Thursday, August 27, 2020 2:00 PM 3:00 PM 14:00 15:00 Google Calendar ICS    Name * First Name Last Name Email * I am... * an ALS patient an ALS caregiver a representative from an ALS advocacy organization a representative from a life science...

08/11/2020

Coming soon to a clinic near you...right here at Wake Forest!

The first participants have been enrolled in the HEALEY ALS Platform Trial at Massachusetts General Hospital, testing three proposed drug regimens.

08/10/2020

We thank the PALS that participated in this study at Wake Forest. It is disappointing that levosimendan did not positively impact breathing in ALS as hoped. We'll keep trying...

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION    28  JULY 2020 at 9.45 p.m. EEST                        Orion’s phase 3 REFALS trial...

08/10/2020

We apologize for the long gap between posts. Covid-19 has challenged our whole medical system to develop telehealth and effectively stopped research. We are finally beginning to ramp up research again as we have confidence in our patient's safety using available PPE. Also, we are winding down telehealth visits so will be returning to 3 in-person ALS clinics/month. We will continue to offer some telehealth spots for those that can't travel but most of our PALS benefit from the in-person visits. Please see updates on research plans at Wake Forest.

03/06/2020

We are thrilled to get started with the MT-1186-A01 ALS study. This is a study of oral edaravone (aka Radicava) and there is no placebo group. We will start screening patients in March 2020 and PALS will need to have ALS < 3 years, be 70%, be able to swallow well, and ambulate independently. Send us a message in MyWakeHealth if you are interested. Please see other study updates above.

01/30/2020

Update on the ALS Platform Study. We are anxious to get going...

BOSTON – The Sean M. Healey & AMG Center for ALS at Mass General has received approval from the U.S. Food and Drug Administration (FDA) to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for amyotrophic lateral sclerosis (ALS...